Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs rivaroxaban vs enoxaparin for venous thromboembolism prophylaxis in cancer patients
IRCT20200407046984N1Phase 4Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of dabigatran, rivaroxaban and enoxaparin in venous thromboembolism (VTE) (3 arms), sponsored by Semnan University of Medical Sciences. Primary endpoints: Thromboembolism and Bleeding. Started Feb 2020; status: completed.
02
Drugs
dabigatranrivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on IRCT20200407046984N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200407046984N1.